COR THERAPEUTICS' PLATELET AGGREGATION INHIBITOR is being developed as a stand-alone therapy for acute thrombosis and for use with thrombolytics in acute care settings. The glycoprotein IIb-IIIa antagonist is the lead compound of COR Therapeutics, a two-year-old, privately-held cardiovascular R&D firm based in South San Francisco. COR expects to initiate human clinicals by 1992 for acute thrombosis associated with heart attacks, unstable angina, and stroke. The company's follow-on compound is a vascular growth inhibitor in development to prevent restenosis following arterial unblocking procedures such as coronary angioplasty. The product, "an antagonist to the platelet-derived growth factor receptor," may work by turning off the mechanisms responsible for the over-production of smooth muscle cells, the company explained. Merrell Dow vet Vaughn Kailian joined COR as president and CEO on March 1. Kailian, 45, succeeded co-founder and ex-Robertson Stephens general partner Lee Douglas, who has been named VP-business development. Kailian rose through the ranks at Merrell Dow to president and general manager for Merrell Dow USA prior to the company's merger with Marion Labs in 1989. He has extensive marketing and sales experience at Merrel Dow, both in the U.S. and overseas. Prior to joining COR, Kailian served as Marion Merrell Dow corporate VP of global commercial development. Other top COR management include VP-Operations and Development Robert Swift, PhD, and Nancy Montgomery, who is the acting chief financial officer. Swift spent five years as Genentech's first director of clinical affairs and before that was with Pfizer for eight years. Prior to joining COR, Montgomery was VP of finance and chief financial officer at Applied Biosystems.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
